Navigation Links
John Garibotto Joins Cellnovo's Board of Directors
Date:6/20/2013

SWANSEA, England, June 21, 2013 /PRNewswire/ --

Cellnovo, the leading innovator in mobile diabetes management technology, announced today the appointment of John Garibotto as non-executive director.

Mr. Garibotto is a 20 year veteran of the medical device industry and has been instrumental in the development, formation, and financing of highly successful medical device companies including Insulet Corporation (IPO May 2007, Nasdaq: PODD) and TransVascular, Inc. (acquired by Medtronic in Sept '04).  He is presently the founder and Chief Technology Officer of Securus Medical Group, Inc.  Mr. Garibotto has earned a B.Sc. in Industrial Technology from the University of Massachusetts at Lowell and a Masters in Business Administration from Northeastern University.

"It is a real pleasure to welcome John as director," said Eric Beard, Cellnovo's Executive Chairman.  "John has vast experience in complex medical device development.  His expertise and guidance will be invaluable as we prepare to submit our mobile-diabetes management system for US approval."

"I'm delighted to join the board of this outstanding company," said John Garibotto.  "Cellnovo has developed a game-changing approach to the treatment and follow up of patients with type 1 diabetes.  I am very impressed by the mobile, real-time technology that Cellnovo have used for their system, which will undoubtedly address the many unmet needs of both patient and care teams."

About Cellnovo

A UK-based medical device company, Cellnovo develops an innovative mobile diabetes management system. Comprised of a mobile connected patch pump, mobile touchscreen handset/controller, blood glucose meter and applications, the Cellnovo system provides intuitive operation, wireless Internet connectivity and real-time tracking, all industry firsts. For further information, please visit http://www.cellnovo.com.


'/>"/>
SOURCE Cellnovo
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
2. John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations
3. Dr. Victor KR Matsudo Joins ActiGraph Scientific Advisory Board
4. StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500
5. Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer
6. Dalia Dergham Joins Grace Century FZ LLC International Project Team
7. SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions
8. Elissa Guerra Joins Pursuit as VP of Client Solutions
9. Graphene joins the race to redefine the ampere
10. Provia Laboratories, LLC Joins Stoneham Chamber of Commerce in Massachusetts
11. Provonix Joins the Medrio Partner Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of ... their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been ... Target to its list of well-respected retailers. This list includes such fine stores ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):